Cargando…

Prioritisation of COVID-19 boosters in the omicron era

Detalles Bibliográficos
Autores principales:	Irving, Stephanie A, Sundaram, Maria E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560778/ https://www.ncbi.nlm.nih.gov/pubmed/36244366 http://dx.doi.org/10.1016/S0140-6736(22)01971-7

Ejemplares similares

COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron
por: Hart, John D, et al.
Publicado: (2022)

Could Beta variant containing COVID-19 booster vaccines tackle Omicron variants?
por: Jin, Pengfei, et al.
Publicado: (2023)

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
por: Sridhar, Saranya, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

A rationale to prioritise vaccination of HSCT patients against COVID-19
por: Leclerc, Mathieu, et al.
Publicado: (2021)

Updated report of COVID-19 vaccine safety monitoring in Japan: booster doses for Omicron variants and vaccinations for infants and young children
por: Yamaguchi, Toshihiro, et al.
Publicado: (2023)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Shedding new light on COVID-19 therapeutics during the omicron era: a deeper dive into real-world data
por: De Vito, Andrea, et al.
Publicado: (2023)

The need to prioritise childhood tuberculosis case detection
por: Nkereuwem, Esin, et al.
Publicado: (2021)

Safety of COVID-19 booster dose: is the juice worth the squeeze?
por: Madhi, Shabir A, et al.
Publicado: (2023)

Prioritising the health and care workforce shortage: protect, invest, together
por: Agyeman-Manu, Kwaku, et al.
Publicado: (2023)

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era
por: Boaventura, Viviane S, et al.
Publicado: (2023)

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
por: Croda, Julio, et al.
Publicado: (2022)

COVID-19 vaccine booster strategy: striving for best practice
por: Tanriover, Mine Durusu, et al.
Publicado: (2022)

COVID-19 boosters and building trust among UK minority ethnic communities
por: Nellums, Laura B, et al.
Publicado: (2022)

Diagnosis of EVALI in the COVID-19 era
por: Kazachkov, Mikhail, et al.
Publicado: (2020)

COVID-19 vaccination protects children and adolescents
por: Irving, Stephanie A, et al.
Publicado: (2023)

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England
por: Kirsebom, Freja C M, et al.
Publicado: (2022)

Challenges and opportunities to end tuberculosis in the COVID-19 era
por: Wingfield, Tom, et al.
Publicado: (2021)

Number needed to vaccinate for COVID-19 booster doses: a valuable metric to inform vaccination strategies
por: Feng, Shuo, et al.
Publicado: (2023)

Examining the pre-war health burden of Ukraine for prioritisation by European countries receiving Ukrainian refugees
por: Marchese, Valentina, et al.
Publicado: (2022)

Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination
por: Irving, Stephanie A, et al.
Publicado: (2023)

Bringing research directly to families in the era of COVID-19
por: Balevic, Stephen J., et al.
Publicado: (2020)

Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster
por: Hung, Ivan F N, et al.
Publicado: (2021)

Offline: Science and politics in the era of COVID-19
por: Horton, Richard
Publicado: (2020)

Participant stress in the COVID-19 era and beyond
por: Goldfarb, Elizabeth V.
Publicado: (2020)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Updated report of COVID-19 vaccine safety monitoring in Japan: Booster shots and paediatric vaccinations
por: Yamaguchi, Toshihiro, et al.
Publicado: (2022)

Cataract risk stratification and prioritisation protocol in the COVID-19 era
por: Cheng, Kelvin KW, et al.
Publicado: (2021)

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
por: Stoliaroff-Pepin, Anna, et al.
Publicado: (2023)

Functional status in the COVID-19 era: ALERT, ALERT, ALERT!
por: Marques, A.
Publicado: (2021)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

Management of mother–newborn dyads in the COVID-19 era
por: Medvedev, Melissa M
Publicado: (2020)

Social license for the use of big data in the COVID-19 era
por: Shaw, James A., et al.
Publicado: (2020)

Omicron variant and booster COVID-19 vaccines
por: Burki, Talha Khan
Publicado: (2022)

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
por: Accorsi, Emma K., et al.
Publicado: (2022)

Local distribution infrastructure and robust vaccine manufacturing facilities in LMICs should be prioritised to tackle ongoing and future pandemic risk
por: Reza, Hasan Mahmud, et al.
Publicado: (2023)

Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era
por: Abid, Muhammad Bilal
Publicado: (2022)

Mental health of health-care workers in the COVID-19 era
por: Greenberg, Neil
Publicado: (2020)

Disease surveillance for the COVID-19 era: time for bold changes
por: Morgan, Oliver W, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b09vndg6c2hgrhb6lais4i9sfn